MS: Is it one disease?

International MS Journal

Volumn 16, Issue 2, 2009, Pages 57-65

  Barnett, Michael H ^a   Parratt, J D E ^a   Pollard, J D ^a   Prineas, J W ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

Heterogeneity; Homogeneity; Multiple sclerosis; Oligodendrocyte; Pathogenesis

Indexed keywords

ALEMTUZUMAB; COMPLEMENT COMPONENT C3D; FINGOLIMOD; GLATIRAMER; IMMUNOGLOBULIN G; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; NATALIZUMAB;

ADAPTIVE IMMUNITY; ALLERGIC ENCEPHALOMYELITIS; APOPTOSIS; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL PROLIFERATION; CLINICAL RESEARCH; CLINICAL TRIAL; GENETIC HETEROGENEITY; HUMAN; IMMUNOPATHOGENESIS; MICROGLIA; MULTIPLE SCLEROSIS; NEUROPROTECTION; OLIGODENDROGLIA; PHAGOCYTOSIS; REVIEW; T LYMPHOCYTE; TH1 CELL; PATHOLOGY;

HUMANS; MULTIPLE SCLEROSIS;

EID: 70349766374     PISSN: 13528963     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Carswell R: Pathological Anatomy: Illustrations of the Elementary Forms of Disease. London: Orme, Brown, Green and Longman, 1838.
2. Brex PA, Ciccarelli O, O'Riordan JI, Sailer M, Thompson AJ, Miller DH. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med 2002; 346: 158-164.
3. Kostulas VK, Link H, Lefvert AK. Oligoclonal IgG bands in cerebrospinal fluid. Principles for demonstration and interpretation based on findings in 1114 neurological patients. Arch Neurol 1987; 44: 1041-1044.
4. Rudick RA, Cookfair DL, Simonian NA, Ransohoff RM, Richert JR, Jacobs LD et al. Cerebrospinal fluid abnormalities in a phase III trial of Avonex (IFNbeta-1a) for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group. J Neuroimmunol 1999; 93: 8-14.
5. Lennon VA, Wingerchuk DM, Kryzer TJ , Pittock SJ, Lucchinetti CF, Fujihara K et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004; 364: 2106-2112.
6. Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005; 202: 473-477.
7. Prineas JW, McDonald WI, Franklin RJM: Demyelinating Diseases. In: Greenfield's Neuropathology, 7th edn (Graham DI, Lantos PL, eds). London: Arnold 2002; pp471-550.
8. Prineas JW, Raine CS. Electron microscopy and immunoperoxidase studies of early multiple sclerosis lesions. Neurology 1976; 26: 29-32.
9. Prineas JW, Kwon EE, Goldenberg PZ, Ilyas AA, Quarles RH, Benjamins JA et al. Multiple sclerosis. Oligodendrocyte proliferation and differentiation in fresh lesions. Lab Invest 1989; 61: 489-503.
10. Navikas V, Link H. Review: cytokines and the pathogenesis of multiple sclerosis. J Neurosci Res 1996; 45: 322-333.
11. Cannella B, Raine CS. The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann Neurol 1995; 37: 424-435.
12. Merrill JE. Proinflammatory and antiinflammatory cytokines in multiple sclerosis and central nervous system acquired immunodeficiency syndrome. J Immunother 1992; 12: 167-170.
13. Prineas JW, Graham JS. Multiple sclerosis: capping of surface immunoglobulin G on macrophages engaged in myelin breakdown. Ann Neurol 1981; 10: 149-158.
14. Lucchinetti CF, Bruck W, Rodriguez M, Lassmann H. Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis. Brain Pathol 1996; 6: 259-274.
15. Storch MK, Piddlesden S, Haltia M, Iivanainen M, Morgan P, Lassmann H. Multiple sclerosis: in situ evidence for antibody- and complement-mediated demyelination. Ann Neurol 1998; 43: 465-471.
16. Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008; 358: 676-688.
17. Storch MK, Stefferl A, Brehm U, Weissert R, Wallström E, Kerschensteiner M et al. Autoimmunity to myelin oligodendrocyte glycoprotein in rats mimics the spectrum of multiple sclerosis pathology. Brain Pathol 1998; 8: 681-694.
18. Barnett MH, Prineas JW. Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann Neurol 2004; 55: 458-468.
19. Babbe H, Roers A, Waisman A, Lassmann H, Goebels N, Hohlfeld R et al. Clonal expansions of CD8(+) T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J Exp Med 2000; 192: 393-404.
20. Gay FW, Drye TJ, Dick GW, Esiri MM. The application of multifactorial cluster analysis in the staging of plaques in early multiple sclerosis. Identification and characterization of the primary demyelinating lesion. Brain 1997; 120(Pt 8): 1461-1483.
21. Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000; 47: 707-717.
22. Stadelmann C, Ludwin S, Tabira T, Guseo A, Lucchinetti CF, Leel-Ossy L et al. Tissue preconditioning may explain concentric lesions in Balo's type of multiple sclerosis. Brain 2005; 128: 979-987.
23. Keegan M, König F, McClelland R, Brück W, Morales Y, Bitsch A et al. Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet 2005; 366: 579-582.
24. Lassmann H, Bruck W, Lucchinetti C. Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. Trends Mol Med 2001; 7: 115-121.
25. Barnett MH, Parratt JDE, Cho ES, Prineas JW. Immunoglobulins and complement in post-mortem multiple sclerosis tissue. Ann Neurol 2009; 65: 32-46.
26. Breij EC, Brink BP, Veerhuis R, van den Berg C, Vloet R, Yan R et al. Homogeneity of active demyelinating lesions in established multiple sclerosis. Ann Neurol 2008; 63: 16-25.
27. Barnett MH, Sutton I. The pathology of multiple sclerosis: a paradigm shift. Curr Opin Neurol 2006; 19: 242-247.
28. Kivisäkk P, Mahad DJ, Callahan MK, Sikora K, Trebst C, Tucky B et al. Expression of CCR7 in multiple sclerosis: implications for CNS immunity. Ann Neurol 2004; 55: 627-638.
29. de Vos AF, van Meurs M, Brok HP, Boven LA, Hintzen RO, van der Valk P et al. Transfer of central nervous system autoantigens and presentation in secondary lymphoid organs. J Immunol 2002; 169: 5415-5423.
30. Fabriek BO, Zwemmer JN, Teunissen CE, Dijkstra CD, Polman CH, Laman JD et al. In vivo detection of myelin proteins in cervical lymph nodes of MS patients using ultrasound-guided fine-needle aspiration cytology. J Neuroimmunol 2005; 161: 190-194.
31. Fischer HG, Reichmann G. Brain dendritic cells and macrophages/microglia in central nervous system inflammation. J Immunol 2001; 166: 2717-2726.
32. Kappos L, Antel J, Comi G et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 2006; 355: 1124-1140.
33. Dev KK, Mullershausen F, Mattes H, Kuhn RR, Bilbe G, Hover D et al. Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis. Pharmacol Ther 2008; 117: 77-93.
34. Barnett MH, Henderson APD, Prineas JW. The macrophage in MS: just a scavenger after all? Pathology and pathogenesis of the acute MS lesion. Mult Scler 2006; 12: 121-132.
35. Zajicek JP, Wing M, Scolding NJ, Compston DA. Interactions between oligodendrocytes and microglia. A major role for complement and tumour necrosis factor in oligodendrocyte adherence and killing. Brain 1992; 115( Pt 6): 1611-1631.
36. Lassmann H. Hypoxia-like tissue injury as a component of multiple sclerosis lesions. J Neurol Sci 2003; 206: 187-191.
37. Lipton HL, Liang Z, Hertzler S, Son KN. A specific viral cause of multiple sclerosis: one virus, one disease. Ann Neurol 2007; 61: 514-523.
38. Dalton CM, Miszkiel KA, Barker GJ, MacManus DG, Pepple TI, Panzara M et al. Effect of natalizumab on conversion of gadolinium enhancing lesions to T1 hypointense lesions in relapsing multiple sclerosis. J Neurol 2004; 251: 407-413.
39. Miller DH, Khan OA, Sheremata WA , Blumhardt LD, Rice GP, Libonati MA et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003; 348: 15-23.
40. Tubridy N, Behan PO, Capildeo R, Chaudhuri A, Forbes R, Hawkins CP et al. The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group. Neurology 1999; 53: 466-472.
41. Jones JL, Coles AJ. Campath-1H treatment of multiple sclerosis. Neurodegener Dis 2008; 5: 27-31.
42. Ziemssen T, Kümpfel T, Klinkert WE, Neuhaus O, Hohlfeld R. Glatiramer acetate-specific Thelper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brainderived neurotrophic factor. Brain 2002; 125(Pt 11): 2381-2391.
43. Butzkueven H, Zhang JG, Soilu-Hanninen M, Hochrein H, Chionh F, Shipham KA et al. LIF receptor signaling limits immune-mediated demyelination by enhancing oligodendrocyte survival. Nat Med 2002; 8: 613-619.
44. Linker RA, Maurer M, Gaupp S, Martini R, Holtmann B, Giess R et al. CNTF is a major protective factor in demyelinating CNS disease: a neurotrophic cytokine as modulator in neuroinflammation. Nat Med 2002; 8: 620-624.
45. Cruz M, Olsson T, Ernerudh J Höjeberg B, Link H. Immunoblot detection of oligoclonal antimyelin basic protein IgG antibodies in cerebrospinal fluid in multiple sclerosis. Neurology 1987; 37: 1515-1519.
46. O'Connor KC, Chitnis T, Griffin DE, Piyasirisilp S, Bar-Or A, Khoury S et al. Myelin basic protein-reactive autoantibodies in the serum and cerebrospinal fluid of multiple sclerosis patients are characterized by low-affinity interactions. J Neuroimmunol 2003; 136: 140-148.
47. Han MH, Hwang SI, Roy DB, Lundgren DH, Price JV, Ousman SS et al. Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets. Nature 2008; 451: 1076-1081.